TY - JOUR
T1 - Biallelic Variants in AFG3L2 Causing Spastic Ataxia Type 5 (SPAX5)
T2 - Report of Two Pediatric Cases from Bogotá, Colombia
AU - Cortés-Rojas, María Camila
AU - Zarante-Bahamón, Ana María
AU - Ramón-Gómez, Jorge Luis
N1 - Publisher Copyright:
© 2025 International Parkinson and Movement Disorder Society.
PY - 2025/9
Y1 - 2025/9
N2 - Background: Spastic ataxia type 5 (SPAX5) is a rare autosomal recessive neurodegenerative disorder caused by biallelic variants in the AFG3L2 gene. It is characterized by spasticity, cerebellar ataxia, dystonia, and myoclonic epilepsy. Objectives: The objective was to describe the clinical features, with a focus on abnormal movements, and therapeutic outcomes in two Colombian patients with SPAX5. Methods: Two non-consanguineous patients were evaluated for movement disorders, including spasticity, dystonia, and myoclonus, along with developmental regression and seizures. Treatment responses to antiepileptic drugs and levodopa were analyzed. Results: Both patients presented with lower extremity spasticity, generalized dystonia, myoclonus, and seizures. Their responses to treatment were highly variable. Conclusions: This study emphasizes the importance of abnormal movements in the clinical presentation of SPAX5 and highlights the variability in treatment outcomes.
AB - Background: Spastic ataxia type 5 (SPAX5) is a rare autosomal recessive neurodegenerative disorder caused by biallelic variants in the AFG3L2 gene. It is characterized by spasticity, cerebellar ataxia, dystonia, and myoclonic epilepsy. Objectives: The objective was to describe the clinical features, with a focus on abnormal movements, and therapeutic outcomes in two Colombian patients with SPAX5. Methods: Two non-consanguineous patients were evaluated for movement disorders, including spasticity, dystonia, and myoclonus, along with developmental regression and seizures. Treatment responses to antiepileptic drugs and levodopa were analyzed. Results: Both patients presented with lower extremity spasticity, generalized dystonia, myoclonus, and seizures. Their responses to treatment were highly variable. Conclusions: This study emphasizes the importance of abnormal movements in the clinical presentation of SPAX5 and highlights the variability in treatment outcomes.
KW - AFG3L2 protein
KW - SPAX5
KW - children
KW - movement disorders
UR - https://www.scopus.com/pages/publications/105003179833
U2 - 10.1002/mdc3.70092
DO - 10.1002/mdc3.70092
M3 - Article
AN - SCOPUS:105003179833
SN - 2330-1619
VL - 12
SP - 1380
EP - 1384
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 9
ER -